Clinical Data Management
Hobson Prior’s Clinical Data Management team has developed a broad industry network, supplying data management specialists on a permanent and interim basis for vacancies and assignments with clients at a local and international level.
Assignments range from individual to team based roles, ongoing and project specific, and typically Hobson Prior’s Clinical Data Management team undertake searches within:
-
Clinical Data Management
-
Clinical Project Data Management
-
Database and EDC Design
Clients
Click here for more information about us, our services, and our pan-European compliance commitment.
Candidates
Click here for information on contracting in the UK, Switzerland and Europe, and access to our contractor portal.
Hot Jobs
Vacancy Search
Latest News
Anthera listing confirms weak IPO market
The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.
The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of Omeros since it went public in October. Anthera and Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list, Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).
Investors still risk averse
Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.
As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.
